2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
217
Recurrence
26
Neoplasms, Plasma Cell
15
Neoplasms
13
Immunoglobulin Light-chain Amyloidosis
13
Leukemia, Myeloid, Acute
9
Lymphoma, Non-Hodgkin
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Smoldering Multiple Myeloma
5
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Hematologic Neoplasms
4
Plasmacytoma
3
Paraproteinemias
3
Myelodysplastic Syndromes
3
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Hematologic Diseases
3
Carcinoma, Non-Small-Cell Lung
3
Amyloidosis
3
Waldenstrom Macroglobulinemia
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Plasmablastic Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Disease
2
Corneal Diseases
2
Blood Protein Disorders
2
Interventions
Surveys and Questionnaires
3
delta 24-sterol reductase
2
Urinary Diversion
2
Surgical Procedures, Operative
2
Propofol
2
daratumumab
1
Vascular Access Devices
1
Uterine Artery Embolization
1
Tranexamic Acid
1
Telemedicine
1
Pilot Projects
1
Patient Transfer
1
Parapsychology
1
Music Therapy
1
Midazolam
1
Mastectomy, Segmental
1
Lidocaine
1
Lead
1
Imiquimod
1
Ibuprofen
1
Fentanyl
1
Exercise
1
Drainage
1
Cystectomy
1
Control Groups
1
Colonoscopy
1
Bandages, Hydrocolloid
1
Anesthesia, Local
1
Ambulatory Care
1
Alfentanil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Patient Satisfaction
×
daratumumab
×
Clear all
NCT05284591
2024-10-01
MYLENE
iOMEDICO AG
Completed
96 enrolled